Spago Nanomedical
Manufacturing · Sweden · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Scheelevägen 22, Lund, Skane, 223 63, Sw...Phone Number
+46 4681188Website
www.spagonanomedical.seRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Spago Nanomedical
Spago Nanomedical AB is a Swedish company focused on clinical development of precision nanomedicine aimed at improving treatment and diagnosis of cancer and other severe diseases. Their proprietary platform utilizes polymeric materials to enhance the effectiveness of therapies, particularly through their products Tumorad and SpagoPix. Tumorad is designed for targeted radionuclide therapy, showing promise in treating cancers like ovarian and triple-negative breast cancer, while SpagoPix enhances MRI imaging for better diagnosis. The company targets healthcare providers and patients in need of advanced treatment options and diagnostic tools.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Spago Nanomedical your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Spago Nanomedical has new funding data
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Spago Nanomedical launches new products
Earning: See what the market has to say on Spago Nanomedical recently announced quarterly report
Check out if Spago Nanomedical is spiking on competitors!
Check if Spago Nanomedical has recently received funding, and reach out quickly before it becomes old news!
Click to see if Spago Nanomedical had a recent Job posting/layoffs
Spago Nanomedical, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Spago Nanomedical
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Company Profile Activity
Activity Insights
Spago Nanomedical is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Spago Nanomedical is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Spago Nanomedical.
Spago Nanomedical Tech Stack
A closer look at the technologies used by Spago Nanomedical
See more technologies
Spago Nanomedical News & Media
BioStock: Spago Nanomedical’s CEO: “huge commercial opportunities are unfolding”
Last week we saw the USD 2 billion buyout of Fusion Pharmaceuticals by AstraZeneca to accelerate the development of next-generation radioconjugates to treat cancer. The deal showcases rising interest in the field of radiopharmaceuticals. BioStock got in touch with Mats Hansen, CEO of Swedish radiopharma company Spago Nanomedical to get his take on the deal and where Spago is in its development of lead programme Tumorad. Read the article at biostock.se: Spago Nanomedical’s CEO: “hugeBioStock: Spago Nanomedical's promising cancer therapy approved for phase I/IIa
Spago Nanomedical has achieved a significant milestone in its cancer therapy development journey. The company's drug candidate, 177Lu-SN201, has received approval to initiate the clinical phase I/IIa study, Tumorad-01, in Australia. To fully appreciate this endeavour, BioStock reached out to Spago’s CEO Mats Hansen. Read the interview with Mats Hansen at biostock.se: Spago Nanomedical's promising cancer therapy approved for phase I/IIa - BioStock (https://www.biostock.se/2023/10/spago-nanomedicaBioStock: Spago Nanomedical’s SAB on Tumorad’s potential
Recently, Spago Nanomedical announced that the company has formed a Scientific Advisory Board for the radiopharmaceutical programme Tumorad. BioStock reached out to Dr Austin Smith to learn more about the field and Tumorad’s potential. Read the interview with Spago Nanomedical's SAB member Dr Austin Smith at biostock.se: https://www.biostock.se/2023/06/spago-nanomedicals-sab-on-tumorads-potential/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/BioStock: Spago Nanomedical reports advancement
Lund-based Spago Nanomedical recently published its financial statements for 2022, where the company reports advancement within its projects with the upcoming start of clinical studies in Tumorad and the initiation of the company's first clinical phase II study with SpagoPix. BioStock reached out to CEO Mats Hansen to hear more about the company's ambitions for 2023. Read the interview with Spago Nanomedical's CEO Mats Hansen at biostock.se: https://www.biostock.se/en/2023/02/spago-nanomedical-r
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Spago Nanomedical
Sign Up For FreeTo access detailed company insights
Spago Nanomedical AB is a Swedish company focused on clinical development of precision nanomedicine aimed at improving treatment and diagnosis of cancer and other severe diseases. Their proprietary platform utilizes polymeric materials to enhance the effectiveness of therapies, particularly through their products Tumorad and SpagoPix. Tumorad is de... Read More
